See more : Huntsman Corporation (HUN) Income Statement Analysis – Financial Results
Complete financial analysis of Ravinder Heights Limited (RVHL.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ravinder Heights Limited, a leading company in the Real Estate – Development industry within the Real Estate sector.
- Medeon Biodesign, Inc. (6499.TWO) Income Statement Analysis – Financial Results
- Encourage Technologies Co., Ltd. (3682.T) Income Statement Analysis – Financial Results
- Thermwood Corporation (TOOD) Income Statement Analysis – Financial Results
- Tianli Holdings Group Limited (0117.HK) Income Statement Analysis – Financial Results
- Locafy Limited (LCFY) Income Statement Analysis – Financial Results
Ravinder Heights Limited (RVHL.NS)
About Ravinder Heights Limited
Ravinder Heights Limited engages in the real estate business in India. It is involved in the acquisition, construction, and development of townships, built-up infrastructure, housing, commercial premises, hotels, resorts, hospitals, educational institutions, recreational facilities, and city and regional level infrastructure. The company was incorporated in 2019 and is based in New Delhi, India. Ravinder Heights Limited is a subsidiary of Panacea Biotec Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 6.22M | 120.43M | 336.00K | 376.00K | 28.07M |
| Cost of Revenue | 0.00 | 42.00M | 1.03M | 22.36M | 22.24M |
| Gross Profit | 6.22M | 78.43M | -693.00K | -21.98M | 5.83M |
| Gross Profit Ratio | 100.00% | 65.13% | -206.25% | -5,845.48% | 20.78% |
| Research & Development | 0.00 | 0.26 | -7.67 | -1.59 | -6.83 |
| General & Administrative | 36.96M | 16.59M | 5.25M | 7.64M | 15.53M |
| Selling & Marketing | 18.76M | 1.84M | 316.00K | 733.00K | 0.00 |
| SG&A | 55.72M | 18.43M | 5.57M | 8.37M | 15.53M |
| Other Expenses | 0.00 | 45.01M | 403.00K | 626.00K | 35.00K |
| Operating Expenses | 55.72M | 76.43M | 45.82M | 41.19M | 44.37M |
| Cost & Expenses | 55.72M | 118.43M | 46.84M | 41.19M | 44.37M |
| Interest Income | 0.00 | 39.51M | 39.82M | 31.03M | 28.03M |
| Interest Expense | 0.00 | 4.31M | 2.34M | 202.00K | 8.00K |
| Depreciation & Amortization | 21.68M | 118.31M | 46.84M | 43.99M | 221.30M |
| EBITDA | -30.57M | 64.43M | -29.42M | -22.29M | 152.75M |
| EBITDA Ratio | -491.94% | 57.01% | 3,090.77% | 3,233.24% | 544.24% |
| Operating Income | -49.51M | 2.08M | -46.52M | -43.63M | 130.98M |
| Operating Income Ratio | -796.59% | 1.73% | -13,845.83% | -11,602.39% | 466.65% |
| Total Other Income/Expenses | 28.41M | -17.39M | 6.62M | -45.71M | -190.94M |
| Income Before Tax | -21.10M | 42.69M | -5.65M | -50.72M | -191.65M |
| Income Before Tax Ratio | -339.49% | 35.45% | -1,682.14% | -13,488.30% | -682.83% |
| Income Tax Expense | 418.00K | -16.11M | -1.40M | 915.00K | 62.83M |
| Net Income | -21.52M | 61.67M | -217.00K | -47.31M | -252.49M |
| Net Income Ratio | -346.21% | 51.21% | -64.58% | -12,581.65% | -899.61% |
| EPS | -0.35 | 1.01 | 0.00 | -0.77 | -4.12 |
| EPS Diluted | -0.35 | 1.01 | 0.00 | -0.77 | -4.06 |
| Weighted Avg Shares Out | 61.48M | 61.25M | 61.25M | 61.25M | 61.25M |
| Weighted Avg Shares Out (Dil) | 61.33M | 61.28M | 61.25M | 61.25M | 62.17M |
Source: https://incomestatements.info
Category: Stock Reports